CareDx, Inc (CDNA) Research

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Market snapshot

Symbol
CDNA
Price
$26.18
Day change
+11.50%
Market cap
$1.4B
P/E ratio
-163.45x
52-week range
10.96-26.26
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months
Analyst price target
$27.00

Recent news

  • CareDx Sharpens Focus On Core Testing Services

    The transaction, approved by both companies' boards, is expected to close by the end of the third quarter of 2026.

Peer companies

  • CorMedix Inc. (CRMD)
  • Castle Biosciences, Inc. (CSTL)
  • DarioHealth Corp. (DRIO)
  • Embecta Corp. (EMBC)
  • Evolent Health, Inc. (EVH)
  • Fulgent Genetics, Inc. (FLGT)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Myriad Genetics, Inc. (MYGN)

Recent insider activity

  • Hanna John Walter JR — S-Sale (17683 shares) on 2026-06-15
  • Valantine Hannah — A-Award (9795 shares) on 2026-06-12
  • Valantine Hannah — S-Sale (12103 shares) on 2026-06-15
  • COURNOYER CHRISTINE — A-Award (9795 shares) on 2026-06-12
  • Riggsbee Richard Bryan — A-Award (9795 shares) on 2026-06-12

Open CareDx, Inc (CDNA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.